The Role of Mitochondrial/metabolic Axis in Development of Tamoxifen Resistance in Breast Cancer

Overview

Journal Hum Cell

Publisher Springer

Specialty Cell Biology

Date 2023 Aug 30

PMID 37646973

Authors

Hany N Azzam

Marwa O El-Derany

Sara A Wahdan

Reham M Faheim

Gouda K Helal

Ebtehal El-Demerdash

Affiliations

Soon will be listed here.

Abstract

Only a few investigations, to our knowledge, have examined the bioenergetics of Tamoxifen (TMX) resistant individuals and reported altered mitochondrial activity and metabolic profile. The primary cause of TMX resistance is firmly suggested to be metabolic changes. Metabolic variations and hypoxia have also been linked in a bidirectional manner. Increased hypoxic levels correlate with early recurrence and proliferation and have a negative therapeutic impact on breast cancer (BC) patients. Hypoxia, carcinogenesis, and patient death are all correlated, resulting in more aggressive traits, a higher chance of metastasis, and TMX resistance. Consequently, we sought to investigate the possible role of the metabolic/hypoxial axis Long non-coding RNA (LncRNA) Taurine up-regulated 1 (TUG-1), Micro-RNA 186-5p (miR-186), Sirtuin-3 (SIRT3), Peroxisome Proliferator Activator Receptor alpha (PPAR-α), and Hypoxia-Inducible Factor-1 (HIF-1) in the development of TMX resistance in BC patients and to correlate this axis with tumor progression. Interestingly, this will be the first time to explore epigenetic regulation of this axis in BC.

Citing Articles

Variation in human gut microbiota impacts tamoxifen pharmacokinetics.

Alam Y, Hakopian S, Ortiz de Ora L, Tamburini I, Avelar-Barragan J, Jung S mBio. 2024; 16(1):e0167924.

PMID: 39584836 PMC: 11708054. DOI: 10.1128/mbio.01679-24.

Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling.

Liu Z, Zheng X, Li N, Wang Z Mol Med Rep. 2024; 31(1).

PMID: 39513601 PMC: 11564906. DOI: 10.3892/mmr.2024.13383.

References

Khalil A, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D . Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009; 106(28):11667-72. PMC: 2704857. DOI: 10.1073/pnas.0904715106. View

Li T, Liu Y, Xiao H, Xu G . Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer. 2016; 24(4):535-543. DOI: 10.1007/s12282-016-0736-x. View

Sullivan L, Gui D, Vander Heiden M . Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer. 2016; 16(11):680-693. DOI: 10.1038/nrc.2016.85. View

Lekka E, Hall J . Noncoding RNAs in disease. FEBS Lett. 2018; 592(17):2884-2900. PMC: 6174949. DOI: 10.1002/1873-3468.13182. View

Alshahrani S, Ibrahim Y, Turki Jalil A, Altoum A, Achmad H, Zabibah R . Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism. Front Oncol. 2022; 12:1042196. PMC: 9723351. DOI: 10.3389/fonc.2022.1042196. View

Gao J, Yuan S, Jin J, Shi J, Hou Y . PPARα regulates tumor progression, foe or friend?. Eur J Pharmacol. 2015; 765:560-4. DOI: 10.1016/j.ejphar.2015.09.027. View

Gaal Z, Csernoch L . Impact of Sirtuin Enzymes on the Altered Metabolic Phenotype of Malignantly Transformed Cells. Front Oncol. 2020; 10:45. PMC: 7033489. DOI: 10.3389/fonc.2020.00045. View

Kronblad A, Hedenfalk I, Nilsson E, Pahlman S, Landberg G . ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene. 2005; 24(45):6835-41. DOI: 10.1038/sj.onc.1208830. View

Hultsch S, Kankainen M, Paavolainen L, Kovanen R, Ikonen E, Kangaspeska S . Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer. 2018; 18(1):850. PMC: 6109356. DOI: 10.1186/s12885-018-4757-z. View

10.

Dorssers L, van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns E . Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs. 2001; 61(12):1721-33. DOI: 10.2165/00003495-200161120-00004. View

11.

Kersten S, Desvergne B, Wahli W . Roles of PPARs in health and disease. Nature. 2000; 405(6785):421-4. DOI: 10.1038/35013000. View

12.

Zong X, Cheng K, Yin G, Wu Z, Su Q, Yu D . SIRT3 is a downstream target of PPAR-α implicated in high glucose-induced cardiomyocyte injury in AC16 cells. Exp Ther Med. 2020; 20(2):1261-1268. PMC: 7388318. DOI: 10.3892/etm.2020.8860. View

13.

Taylor C, Furuta G, Synnestvedt K, Colgan S . Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci U S A. 2000; 97(22):12091-6. PMC: 17299. DOI: 10.1073/pnas.220211797. View

14.

Tomkova V, Sandoval-Acuna C, Torrealba N, Truksa J . Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. Free Radic Biol Med. 2019; 143:510-521. DOI: 10.1016/j.freeradbiomed.2019.09.004. View

15.

Wu Z, Zhao S, Li C, Liu C . LncRNA TUG1 serves an important role in hypoxia-induced myocardial cell injury by regulating the miR‑145‑5p‑Binp3 axis. Mol Med Rep. 2017; 17(2):2422-2430. PMC: 5783484. DOI: 10.3892/mmr.2017.8116. View

16.

Lin L, Sun J, Wu D, Lin D, Sun D, Li Q . MicroRNA-186 is associated with hypoxia-inducible factor-1α expression in chronic obstructive pulmonary disease. Mol Genet Genomic Med. 2018; 7(3):e531. PMC: 6418446. DOI: 10.1002/mgg3.531. View

17.

Ahn C, Metallo C . Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015; 3(1):1. PMC: 4305394. DOI: 10.1186/s40170-015-0128-2. View

18.

Yang J, Altahan A, Jones D, Buffa F, Bridges E, Interiano R . Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A. 2015; 112(49):15172-7. PMC: 4679044. DOI: 10.1073/pnas.1422015112. View

19.

Huh J, Shin J, Jang E, Park S, Park D, Ko R . Sirtuin 3 (SIRT3) maintains bone homeostasis by regulating AMPK-PGC-1β axis in mice. Sci Rep. 2016; 6:22511. PMC: 4772385. DOI: 10.1038/srep22511. View

20.

Generali D, Berruti A, Brizzi M, Campo L, Bonardi S, Wigfield S . Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006; 12(15):4562-8. DOI: 10.1158/1078-0432.CCR-05-2690. View